Nasdaq:US$20.09 (+0.00) | HKEX:HK$31.40 (-0.65) | AIM:£3.15 (-0.09)
Search Result
Previous Article   |   Next Article
Announcements & Press Releases | 8 Apr 2024

HMPL-A067 (HMA800067), a novel CD38-targeting antibody-drug conjugate (ADC), demonstrated superior antitumor activity to daratumumab in preclinical B-cell malignancies models